Mast-cell modulators and uses thereof

Patent metadata

Field	Value
Publication number	US-11084789-B2
Application number	US-202016738371-A
Country	US
Kind code	B2
Filing date	Jan 9, 2020
Priority date	Jan 14, 2016
Publication date	Aug 10, 2021
Grant date	Aug 10, 2021

Abstract

Provided are novel compounds of Formula I:pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders associated with mast cells. Also provided are pharmaceutical compositions comprising the novel compounds of Formula I and methods for their use in treating one or more diseases and disorders associated with mast cells.

First claim

The invention claimed is:

1. A method of delaying the onset of, reversing, or reducing the risk of acquiring peripheral neuropathy (PN) in a subject having diabetes, comprising administering to the subject an effective amount of a compound having the Formula:

or a pharmaceutically acceptable salt thereof, polymorph, or solvate thereof.

2. The method of claim 1 , wherein the peripheral neuropathy is peripheral diabetic neuropathy.

3. A method of accelerating the healing of a wound in a subject having diabetes, comprising administering to the subject an effective amount of a compound having the Formula:

or a pharmaceutically acceptable salt thereof, polymorph, or solvate thereof.

Assignees

• Beth Israel Deaconess Medical Ct Inc

Inventors

• Sun Lijun
• Veves Aristidis

Classifications

• C07D417/12

  linked by a chain containing hetero atoms as chain links · CPC title

• C07D231/56

  Benzopyrazoles; Hydrogenated benzopyrazoles · CPC title

• C07D209/42 Primary

  Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals · CPC title

• A61P17/02

  for treating wounds, ulcers, burns, scars, keloids, or the like · CPC title

• C07D209/36

  in position 3, e.g. adrenochrome · CPC title